Merck + Co., Inc.

Gaochao Zhou

Kun Liu

Alan D Adams

James Francis Dropinski

Derek J Von Langen

A Brian Jones

Joel Peter Berger

Alexander Elbrecht

Karen Lamb MacNaul

Guo-Qiang Shi

Jeffrey Donald Hermes

David E Moller

Richard T Cummings

A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Provided is a method of identifying agonists and antagonists of nuclear receptors that comprises measuring agonist-dependent fluorescence resonance energy transfer (FRET) between a fluorescently labeled nuclear receptor or ligand binding domain and fluorescently labeled CREB-binding protein (CBP), p300, other nuclear co-activator, or binding portion thereof. The method is simple, rapid, and inexpensive. Nuclear receptors and nuclear receptor co-activators labeled with fluorescent reagents for use in the above-described method are also provided.

Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer

Growing community of inventors

Scotch Plains, NJ, United States of America

Gaochao Zhou